Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
177 Cards in this Set
- Front
- Back
All organs and systems in the body are subject to anaphylaxis.
|
True
|
|
What is the appropriate dosage when administering 1:2000 aqueous Intramuscular via EpiPen Junior?
|
0.15mL
|
|
Stimulation of which division of the autonomic nervous system causes the release of epinephrine?
|
Sympathetic division
|
|
Epinephrine is referred to as adrenaline and causes ______?
|
vasoconstriction/bronchodilation
|
|
What effect does epinephrine have on cardiac activity?
|
Epinephrine stimulates the receptor cells of the smooth cardiac muscle causing the heart rate and blood pressure to increase.
|
|
What is the most dangerous aspect of a vasovagal episode?
|
Injuries obtained from the fall
|
|
There are two types of syringe tips - plan and locking.
|
True
|
|
What is the most common type of syringe used for administration of parenteral injections?
|
plastic
|
|
Syringe selection is based on _____?
|
purpose of the injection, the volume of vaccine to be injected and the need for accuracy in dosage
|
|
The most accurate size syringe is the _____?
|
1 mL
|
|
Prepackaged units_________
|
guarantee accuracy, are convenient for normal use, are especially convenient for emergency situations
|
|
The gauge of a needle is an inverse measurement of the diameter. As the diameter increases, the gauge decreases.
|
True
|
|
Which of the following should be considered when selecting a needle for administering injections?
|
size of the muscle, thickness of adipose tissue at injection site, volume of material to be administered
|
|
Because vaccine administered parenterally is almost totally absorbed rather than being partially destroyed by the digestive system, a smaller dosage will achieve the same therapeutic effect.
|
True
|
|
Only the purpose and characteristics of the vaccine determine the route of administration.
|
False
|
|
Of the different sites available for an intramuscular injection for an adult, which site has the best blood supply and the most rapid response?
|
Deltoid Muscle
|
|
What steps can you take to prevent nosocomial infections and associated complications?
|
hand washing, maintain sterility of equipment, cleaning of the injection site
|
|
When preparing a syringe for vaccine administration you notice the package is partially open. What should you do?
|
get a new syringe
|
|
The proper procedure for drawing vaccine from a vial is?
|
Remove the protective cap on the vial and clean off the diaphragm with an alcohol swab. Pull back the plunger to aspirate the needed amount of air and insert the needle in the center of the rubber diaphragm. Inject the air and aspirate the vaccine.
|
|
When reconstituting a multi-dose vaccine you should_________?
|
Label the vial with the date and time mixed
|
|
What steps should you take before administering a vaccine?
|
Follow the 6 rights of medication administration
|
|
What is the mot commonly used area for the administration of Intradermal injections?
|
ventral surface of forearms
|
|
The most common site for subcutaneous injections is the
|
triceps
|
|
Which intramuscular injection site presents the most risk because of proximity to the large sciatic nerve?
|
Gluteal sites
|
|
Choose the correct intramuscular injection needle angle when administering an injection into the deltoid muscle
|
90 degrees
|
|
Vaccines can be given in the gluteal area to pediatric patients
|
False
|
|
Active immunity ________?
|
is a reaction that stimulates antibody production, appears following exposure to an antigen, is a direct result of an immune response
|
|
Artificially acquired passive immunity results from the administration of a specific _____?
|
antibody
|
|
The prescribed dosage and route for anthrax vaccine is ____ with a possible mild ____ reaction.
|
0.5mL IM; local, systemic
|
|
The recommended booster dose for the Anthrax vaccine is _____
|
Annually if continued immunity is needed
|
|
What is the routine schedule for Hepatitis-B vaccination?
|
Day-30, day-60, day-180
|
|
A patient with a history of an anaphylactic reaction after ingestion of eggs should not receive a(n) ______ vaccination before they are skin tested.
|
Influenza
|
|
The Td booster dose is administered _________
|
every 10 years throughout lifetime
|
|
What is the dosage requirement for a child for Recombivax (Hepatitis-B) vaccine?
|
0.50mL IM Deltoid muscle (<20 years of age)
|
|
A 6-month-old healthy child presents for routine immunizations. Child is up to date through 4 months of age. What vaccines are required?
|
DTap, HiB, Prevnar, IPV
|
|
An 8-week healthy child presents for routine immunization. The child has no immunizations to date. What vaccines are required?
|
Comvax, Prevnar, IPV, DTap
|
|
Primary immunization series for the Pediarix vaccine is?
|
2, 4, and 6 months
|
|
Smallpox vaccine (ACAM2000) is administered ____ route.
|
Percutaneous
|
|
How many jabs does an individual receive if receiving the Smallpox vaccine for the first time?
|
15
|
|
TB test are administered intradermally on the volor aspect of either forearm. About how far below the bend in the elbow should it be placed?
|
4 inches
|
|
International health threat assessments are conducted by which governing agency?
|
Defense Intelligence Agency Armed Forces Medical Intelligence Center (AFMIC)
|
|
AFJI 44-102 outlines immunization guidelines for active duty personnel on alert status
|
True
|
|
Can waivers for religious reasons be revoked if the mission is compromised?
|
Yes
|
|
Who has the responsibility for ensuring that military and nonmilitary personnel who are subject to rapid deployment, receive all required immunizations?
|
Do you have allergies to any medications, foods or vaccines?
Are you or a family member immunocompromised/deficient due to medication, treatment, or disease? Are ou pregnant or have the intention of becoming pregnant in the next three months? |
|
When annotating immunization records =, using a signature stamp is authorized.
|
False
|
|
When transcribing an adult's immunization record, only transcribe immunizations that are _______
|
once in a lifetime, current and in a series
|
|
IAW WHO Article 80, what document is considered adequate proof of vaccination for armed forces personnel?
|
DD Form 2766C, Vaccine Administration Record
|
|
At the time of initial immunization of Air Force non-military personnel, a DD form 2766C is established. Which other form can you use to document the immunization?
|
International Certificate of Vaccination or Prophylaxis (ICVP)
|
|
Anthrax
indicated ages |
individuals between 18-65
|
|
Anthrax
Primary Series Booster |
consists of 5 intramuscular doses at 0 and 4 weeks and 6, 12 and 18 months
Yearly booster 0.5mL still risk |
|
Anthrax
contraindications |
Severe allergic reaction (e.g. anaphylaxis) after a previous dose of BioThrax
|
|
Anthrax
Storage/Management |
2 to 8 degrees C
(36 to 46 degrees F) Do not use BioThrax after expiration date printed on the label |
|
Hepatitis A
Indications |
19 year and older
All active duty arrears of high endemicity persons in high-risk sexual activity |
|
Hepatitis A
dosage |
1.0mL in deltoid
|
|
Hepatitis A
primary series |
single dose given followed with a booster dose 6-12 for Havrix
6-18 months later for Vaqta |
|
Hepatitis B Vaccine
Indications |
Infants including those born to HBsAg positive mothers
Those born after 21NOV1991 Adolescents Health Care Professionals Morticians/Embalmers Blood Bank/Plasma workers Prisoners |
|
Hepatitis B Vaccine
Dosage |
1.0mL IM deltoid muscle (>19 years)
|
|
Hepatitis B Vaccine
Primary Series |
Three (3) doses regimen.
First dose at elected date, second dose one (1) month later, third dose six (6) months after the first |
|
Hepatitis B Vaccine
Contraindications |
Hypersensitivity to yeast
Any component of the vaccine |
|
Human Papillomavirus (GARDASIL)
indications |
females 9-26 years of age
prevention of HPV types 6,11,16 &18 |
|
Human Papillomavirus
(GARDASIL) dosage |
0.5mL IM
|
|
Human Papillomavirus
(GARDASIL) primary series |
First dose: at elected date
Second dose: 2 months after the first Third dose: 6 months after the first |
|
Human Papillomavirus
(GARDASIL) contraindication |
Hypersensitivity to the active substances or to any of the excipients of the vaccine
|
|
Influenza (Flu) injectable
indications |
All active duty
Healthcare workers persons age less than or equal to 65 Women in the second and third trimester of pregnancy |
|
Influenza (Flu) Injectable
dosage |
0.5mL IM
|
|
Influenza (Flu) injectable
Primary Series |
Annually
|
|
Influenza (Flu) Injectable
contraindications |
hypersensitivity (allergy) anaphylactic reactions to eggs or egg products
Sensitive to Thimerosal |
|
Influenza (Flu) Intranasal
indications |
All active duty
Healthcare workers persons 2-49 years healthy children and adults |
|
Influenza (Flu) Intranasal
dosage |
0.20mL
|
|
Influenza (Flu) Intranasal
primary series |
Annually
|
|
Influenza (Flu) Intranasal
contraindications |
No administration parenterally
Hypersensitivity to eggs or egg products children/adolescents 2-17 years history of Guillain-Barre syndrome |
|
Japanese Encephalitis Vaccine
indications |
month or longer in endemic areas during transmission season
lab workers exposed to virus specific guidance for AD by MAJCOM |
|
Japanese Encephalitis Vaccine
dosage |
1.0mL patient 3 yrs and older SQ
0.50mL 35 months to 1 yr SQ |
|
Japanese Encephalitis Vaccine
primary series |
three (3) doses given 0, 7 and 30 days
third dose at least 10 days before travel |
|
Japanese Encephalitis Vaccine
contraindication |
allergic reaction to prior dose or vaccine components
persons with multiple allergies; hx of urticria or angiodema pregnancy |
|
Measles, Mumps, Rubella (M-M-RII)
indications |
12 months or older
adults born in 1957 or later college students healthcare personnel women of childbearing age international travel |
|
Measles, Mumps, Rubella (M-M-RII)
dosage |
0.5mL SQ
|
|
Measles, Mumps, Rubella (M-M-RII)
primary series |
one (1) dose for adults
|
|
Measles, Mumps, Rubella (M-M-RII)
second dose |
If recommended, minimum of 4 weeks between the 1st and 2nd shot
|
|
Measles, Mumps, Rubella (m-M-RII)
contraindications |
Hypersensitivity to any component; include gelatin
Pregnancy Febrile infection Anaphylactic/anaphylacoid to neomycin Pt receiving immunosuppressive therapy pt w/ HIV, disease affecting the bone marrow or lymphatic system |
|
Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
dosage |
0.5mL SQ
|
|
Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
Primary Series |
Single dose
|
|
Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
indications |
deficiencies in late Complement components
functional/actual asplenia lab travelers/residents hyperendemic areas |
|
Meningococcal Polysaccharide Vaccine Group A,C,Y and W-135 Combined (Menomune-A/C/Y/W-135)
contraindications |
hx or adverse reaction to Thimerosal
defer immunization during the course of any acute illness |
|
Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
indications |
licensed for ages 2-55 years
travelers to hyperendmic areas |
|
Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
dosage |
0.5mL IM
|
|
Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
primary series |
single dose
|
|
Meningococcal (Group A,C,Y and W-135) Polysaccharide Diptheria Toxoid Conjugate Vaccine Menactra
contraindications |
hx of adverse reaction to Thimerosal
Defer immunization during course of any acute illness |
|
Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV) indications |
travelers to endemic regions
Healthcare workers exposed Lab workers exposed All active duty required to have one (1) dose |
|
Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV) dosage |
0.5mL SQ/IM (IPV)
|
|
Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV) primary dose |
unvaccinated adults:
two doses 4-8 weeks apart followed by third 6-12 months after 2nd dose day-0, day-30, 6-12 months |
|
Inactivated Polio Vaccine
(IPV, e-IPV, ep-IPV) contraindications |
hx of hypersensitivity to vaccine; 2-phenoxyethanol, formaldehyde, neomycin, streptomycin and polymyxin
Person w/ acute febrile illiness |
|
Pneumococcal Vaccine (PPV 23)
|
pts 2 yr and older; routine vaccination for persons 50 years or older
|
|
Pneumococcal Vaccine (PPV 23) dosage
|
0.50 mL SQ/IM
one dose |
|
Rabies Vaccine
primary series - pre-exposure |
three (3) doses
day -0, day - 7 and day-21 to 28 |
|
Rabies Vaccine
primary series - post exposure |
give rabies immune globulin asap, followed by five (5) doses day-0, day-3, day-7, day-14 and day-28
|
|
Rabies Vaccine
dosage |
1.mL IM deltoid
|
|
Shingles {Zostavax}, Live
primary series |
single dose, 0.65mL SQ
|
|
Shingles {Zostavax}, Live
contraindications |
hx of allergic reaction to gelatin, neomycin, or compnent of vaccine
hx of immunodeficiency Immunosuppressive therapy Active untreated TB Pregnant |
|
Smallpox (AMSAM2000), Live
primary |
administred percutaneous route (scarification) using 15 jabs
|
|
Smallpox (AMSA2000), Live
storage |
freezer temperature of -15 to -25 degrees C
|
|
Tetanus/Diphtheria (Td)
indications |
Pt 7 years and older
New recruites |
|
Tetanus/Diphtheria (Td)
dosage |
0.5mL IM
|
|
Tetanus/Diphtheria (Td)
primary Series |
Two (2) doses given at an interval of 4 to 8 weeks, following a third reinforcing dose 6 to 12 months after the second dose
Booster at 10-year intervals |
|
Tdap (ADACEL)
|
active booster immunization of tetanus, diphtheria and pertussis, 11-64 years
|
|
Tdap (ADACEL)
dosage |
single dose 0.5mL IM
|
|
Tdap - Boostrix
dosage |
05.50 mL, IM
|
|
Tdap - Boostrix
|
10-64 yr as a booster to the promary series
|
|
Twinrix (Hepatitis A inactivated & Hepatitis B (Rocombiant) Vaccine
indications |
chronic liver disease
risk through work Healthcare workers daycare or correctional employees men having sex with men military recruits |
|
Twinrix (hepatitis A inactivated & Hepatitis B (Recombiant)
dosage |
1.0mL IM, primary for adults three (3) doses, day-0, 1 month and 6-month mark
|
|
Typhoid Vaccine (Oral, Ty21a), Live
indications |
All active duty on mobiility status
|
|
Typhoid Vaccine (Oral, Ty21a), Live
dosage |
4 capsules orally, one (1) taken every other day
|
|
Typhoid Vaccin (Typhim Vi), parenteral
dosage |
0.5mL IM
|
|
Varicella Virus Vaccine (Chickenpox) (Varivax), Live
indications |
> or equal to 12 months of age
high-risk occupational groups |
|
Varicella Virus Vaccine (Chickenpox) (Varivax), Live
dosage |
0.5mL SQ
two (2) doses four to eight weeks apart |
|
Yellow Fever, Live
indications |
persons >or equal to 9 months of age traveling/living in areas of South America and Africa
Lab personnel who may be exposed |
|
Yellow Fever, Live
|
single dose, 0.5ml SQ, booster every 10 yrs
|
|
Yellow Fever, Live
contraindications |
Allergic to eggs
Mercury sensitivity antibiotic indused allegic reaction hypersensitvity to vaccine components |
|
Adult Immunization Schedule
|
Td/Tdap - 1 time dose, then booster every 10 yr (19-65)
HPV - 3 doses, females 19-26 Varicella - 2 doses 19 and up Zoster - 1 dose, 60 yr and up MMR - 1 or 2 doses, 19-49; 1 dose 50 and up Influenza - 1 dose annually 19 and up Pneumococcal - 1 or 2 dose, 19-64; 1 dose 65 and older Hepatitis A - 2 doses, 19 and older Hepititis B - 3 doses 19 and older Meningococcal - 1 or more doses, 19 and older |
|
Comvax
(Hib and Hep B combination) schedule |
administer at 2, 4 and 12-15 months of age
|
|
Comvax
(Hib and Hep B combination) dosage |
0.50mL; IM
|
|
Comvax
(Hib and Hep B combination) contraindications |
Hypersensitvity to yeast
any components |
|
DT
schedule |
2 months
4 months 6 months 15-18 months 4 - 6 yrs of age |
|
DT
dosage |
0.50mL; IM
|
|
DT
contraindications |
hypersensitivity to component
hypersensitivity to Thimerosal |
|
DTap/DTP
schedule |
2, 4, 6, 15-18 months
4-6 years of age Doses 2&3 can be given 4 weeks after previous dose while dose 4 should be given at least 6 months after dose3. If dose 4 is givven before child's 4th birthday give dose 5 at lease 6 months later. If given after the 4th birthday dose 5 is not necessary |
|
DTap/DTP
dosage |
05.50mL; IM
|
|
DTap/DTP
contraindications |
hypersensitivityto components
hypersensitivity to Thimerosal Gelatin |
|
DTap-IPV (Kinrix)
schedule |
5th dose in DTap series
4th dose in IPV series in children 4-6 years of age |
|
DTap-IPV (Kinrix)
dosage |
0.5mL, IM
preferred deltoid upper arm |
|
DTap-IPV (Kinrix)
contraindications |
hypersensitivity
encephalopathy progressive neurologic disorder |
|
DTap-IPV/Hib (Pentacel)
schedule |
2, 4, 6, 15 - 18 months
|
|
DTap-IPV/Hib (pentacel)
dosage |
0.5mL, IM
|
|
DTap-IPV/Hib (Pentacel)
contraindications |
hypersensitivity
encephalopathy progressive neurologic disorder |
|
Haemophilus Influenza type B (HIB)
HibTITER (Wyeth) PedvaxHIB (merck) ActHIB (Sanofi-Pasteur) contraindications |
prior reaction
hx of hypersensitivitiy to components, Thimersol |
|
Hepatitis A
schedule |
1- 18 yrs old
two doses 6 - 12 months apart |
|
Hepatitis A
dosage |
0.50mL; IM
|
|
Hepatitis A
contraindications |
anaphylaxis to components
|
|
Hepatitis B (HBV)
schedule |
"A" - birth, 2 months, 1-4 months oldand 6-18 months old
"B" - day 0, day 30 and day 180 (for older children) |
|
Hepatitis B (HBV)
dosage |
0.50mL; IM
|
|
Hepatitis B (HBV)
contrainidications |
anaphylaxis to previous dose, vaccine component, yeast and Thimerosal
|
|
Inactivated Polio (IPV)
schedule |
2, 4, 6-18 months and 4-6 years of age
|
|
Inactivated Polio (IPV)
dosage |
0.50mL; SQ or IM
|
|
Inactivated Polio (IPV)
contraindications |
anaphylaxis to components or previous dose
|
|
Comvax
(Hib and Hep B combination) schedule |
administer at 2, 4 and 12-15 months of age
|
|
Comvax
(Hib and Hep B combination) dosage |
0.50mL; IM
|
|
Comvax
(Hib and Hep B combination) contraindications |
Hypersensitvity to yeast
any components |
|
DT
schedule |
2 months
4 months 6 months 15-18 months 4 - 6 yrs of age |
|
DT
dosage |
0.50mL; IM
|
|
Influenza (Flu) injectable
schedule |
age 9 and older: one dose annually
age 8 or younger previously unvaccinated: two doses 1 month apart |
|
Influenza (Flu) injectable
dosage |
3 and older 0.50mL IM
6 - 35 months 0.25mL IM |
|
Influenza (Flu) injectable
contraindications |
eggs and Thimersol or reaction to previous dose
|
|
Influenza (Flu) intranasal
|
2-49 years
0.20mL |
|
Measles, Mumps, Rubella
(M-M-RII), Live schedule |
two doses 12-15 months and 4-6 years old
|
|
Measles, Mumps, Rubella
(M-M-RII), Live dosage |
0.50mL; SC
|
|
Measles, Mumps, Rubella
(M-M-RII), Live contraindications |
anaphy;axis to components, eggs or neomycin
|
|
Measles, Mumps, Rubella
and Varicella (MMRV-ProQuad), Live schedule |
routine - 12-18 months
individuals 12 months - 12 years should recieve a single 0.5mL dose of ProQuad SQ |
|
Measles, Mumps, Rubella
and Varicella (MMRV-ProQuad), Live contraindications |
reaction to neomycin
hypersensitivity to gelatin immunosuppresive therapy untreated TB |
|
PEDIARIX (diphtheria, tetanus toxoid and pertusis absorbed, Hepatitis B (Recombiant) and Inactivated Poliovirus Vaccine Combined)
schedule |
3 doses - 2 months, 4 months and 6 months of age
|
|
PEDIARIX (diphtheria, tetanus toxoid and pertusis absorbed, Hepatitis B (Recombiant) and Inactivated Poliovirus Vaccine Combined)
contraindications |
sensitivity to components
yeast neomycin polymyxin previous dose |
|
PEDIARIX (diphtheria, tetanus toxoid and pertusis absorbed, Hepatitis B (Recombiant) and Inactivated Poliovirus Vaccine Combined)
dosage |
0.50mL; IM
|
|
Pneumococcal Conjugate Prevnar (PCV7)
schedule |
2, 4, 6, & 12- 15 months of age
older children at risk: 7-11 months old two doses two months apart, another dose 15-18 months. 12-23 months two doses two months apart and 24months - 9 years one dose |
|
Pneumococcal Conjugate Prevnar (PCV7)
dosage |
0.50mL; IM
|
|
Pneumococcal Conjugate Prevnar (PCV7)
contraindications |
anaphylaxisis to components, diphtheria toxioid
|
|
ROTARIX, Live
schedule |
administer first dose to infants beginning 6 weeks of age
second dose after at leaset 4 weeks and prior to 24 weeks of age |
|
ROTARIX, Live
dosage |
1-mL orally
|
|
ROTARIX, Live
contraindication |
Hx of uncorrected congential malformation of the GI tract
|
|
RotaTeq [Rotavirus Vaccine, Live, Oral, Pentavalent]
schedule |
3 ready to use, start at 6 to 14 weeks of age, with subsequent doses administered at 4- to 10- week intervals
|
|
RotaTeq [Rotavirus Vaccine, Live, Oral, Pentavalent]
dosage |
2 mL Orally
|
|
RotaTeq [Rotavirus Vaccine, Live, Oral, Pentavalent]
contraindications |
Hx of hypersensitivity to components
sensitivity to first dose |
|
TriHIBit (DTap and HIB)
schedule |
12-18 months old ONLY
|
|
TriHIBit (DTap and HIB)
dosage |
0.50ml; IM
|
|
TriHIBit (DTap and HIB)
contraindications |
Hx of pertussus or components containing pertussis in vaccine
Thimerosal Encephalopathy |
|
Varicella, Live
schedule |
Children: routine 12-18 months and 4-6 yrs of age, if second dose administered a minimum of 3 months later.
Adolescents: 13 yrs and older at elected date and a second 4-6 weeks later |
|
Varicella, Live
dosage |
0.5mL; SQ
|
|
Varicella, Live
contrindications |
anaphylaxsis to components
neomycin gelatin MSG |
|
Purified Protein Derivative (PPD) 5TU Strength; delayed skin test
|
read 48 to 72 hours after injection
0.1mL of 5TU strength intradermal |